Markets:

Overview

News

Currencies

International

Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

53.25 +0.05 (+0.09%)

Delayed Quote Updated: 12:54 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

October 22, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

October 14, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 09, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

October 08, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

October 07, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

September 15, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Why Pulse Biosciences Stock Popped Today ↗

September 09, 2026

The medical device maker now has a new bull touting its growth potential.

Via The Motley Fool

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform ↗

August 16, 2026

Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President,...

Via MarketBeat

Topics Intellectual Property

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

NANOPULSE-AF enrollment hit halfway point ahead of schedule with 82 patients.

Via The Motley Fool

Topics Earnings

Pulse Biosciences Q2 Earnings Call Highlights ↗

August 07, 2026

Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial...

Via MarketBeat

Topics Earnings Intellectual Property

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

August 06, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

July 30, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

July 29, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

July 21, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

June 10, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 27, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. ↗

May 17, 2026

Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains.

Via The Motley Fool

Topics Regulatory Compliance

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

May 12, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Q1 Earnings Call Highlights ↗

May 08, 2026

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new...

Via MarketBeat

Topics Earnings

PLSE Q1 2026 Earnings Transcript ↗

May 08, 2026

PLSE Q1 2026 Earnings Transcript

Via The Motley Fool

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

May 08, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript ↗

May 04, 2026

Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript

Via The Motley Fool

PLSE Q4 2025 Earnings Transcript ↗

May 04, 2026

PLSE Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

May 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

April 25, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

April 20, 2026

From Pulse Biosciences

Via Business Wire

Pulse Biosciences to Host Analyst Event on April 25, 2026

April 17, 2026

From Pulse Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.